0 references
Perioperative Toripalimab Plus Neoadjuvant Chemotherapy Improves Outcomes in Resectable Esophageal Cancer: An Interim Analysis of a Phase III Randomized Clinical Trial (HCHTOG1909)
SSRN Electronic Journal2023
Zheng Yan, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qi, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li, Zongfei Wang, Shilei Liu, Jianping Zhu, Haibo Ma, Zhenzhen Liu, Fei Zhao, Jun Zhang, He Zhang, Daoyuan Wu, Jinrong Qu, Jie Ma, Peng Zhang, Wenjie Ma, Ming Yan, Yongkui Yu, Qing Li, Jiangong Zhang, Wenqun Xing
Related Papers
- → Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report(2011)25 cited
- → Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity(2016)14 cited
- EHR-based Clinical Trial Alert Effects on Recruitment to a Neurology Trial across Institutions: Interim Analysis of a Randomized Controlled Study.(2013)
- → Is Neoadjuvant Chemoradiotherapy Safe for Elderly Patients with Esophageal Cancer?(2015)
- [Perioperative chemotherapy improves long-term survival of esophageal cancer patients: a systemic literatures review].(2016)